Royalty Pharma (RPRX) Capital Expenditures (2019 - 2026)

Royalty Pharma has disclosed Capital Expenditures across 8 years of filings, most recently posting $452.4 million for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $452.4 million, up 42697.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.1 billion (down 11.22% YoY), and the FY2025 annual result was $1.7 billion, down 32.25% from the prior year.
• Capital Expenditures came in at $452.4 million for Q1 2026 at Royalty Pharma, down from $733.7 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $1.3 billion in Q3 2022 to a low of $85000.0 in Q1 2022.
• The 5-year median for Capital Expenditures is $452.4 million (2026), against an average of $500.8 million.
• Across the five-year window, Capital Expenditures plunged 99.98% in 2022 and surged 707788.24% in 2023, its largest moves.
• Royalty Pharma's Capital Expenditures stood at $250.2 million in 2022, then jumped by 300.51% to $1.0 billion in 2023, then slumped by 50.47% to $496.4 million in 2024, then jumped by 47.8% to $733.7 million in 2025, then sank by 38.34% to $452.4 million in 2026.
• The last three Capital Expenditures figures came in at $452.4 million (Q1 2026), $733.7 million (Q4 2025), and $961.9 million (Q3 2025), per Business Quant data.